Y Intercept Hong Kong Ltd Sells 10,068 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Y Intercept Hong Kong Ltd reduced its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 79.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,631 shares of the specialty pharmaceutical company's stock after selling 10,068 shares during the period. Y Intercept Hong Kong Ltd's holdings in Jazz Pharmaceuticals were worth $324,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. CWA Asset Management Group LLC purchased a new position in Jazz Pharmaceuticals during the 3rd quarter valued at $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock worth $19,394,000 after acquiring an additional 100,112 shares in the last quarter. Centre Asset Management LLC purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $9,335,000. Moloney Securities Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $464,000. Finally, Pacer Advisors Inc. lifted its position in Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock valued at $233,892,000 after buying an additional 278,465 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded up $3.45 during midday trading on Friday, reaching $139.90. 595,771 shares of the company's stock traded hands, compared to its average volume of 748,508. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06. The stock's 50-day moving average is $127.85 and its 200 day moving average is $119.83. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a market cap of $8.50 billion, a P/E ratio of 19.70, a PEG ratio of 1.04 and a beta of 0.56.

Remove Ads

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,813 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. This represents a 36.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the transaction, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,113 shares of company stock valued at $2,551,834. Company insiders own 4.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on JAZZ. Morgan Stanley reissued an "overweight" rating and set a $183.00 price target (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday. Barclays reaffirmed an "overweight" rating and set a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. UBS Group raised Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $145.00 to $179.00 in a report on Friday. HC Wainwright reaffirmed a "buy" rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Finally, Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Buy" and a consensus target price of $189.40.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.